A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy

NACompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 1992

Conditions
HIV Infections
Interventions
DRUG

Zalcitabine

DRUG

Didanosine

Trial Locations (16)

10011

Clinical Directors Network of Region II, New York

10037

Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York

10456

Bronx Lebanon Hosp Ctr, The Bronx

19899

Wilmington Hosp / Med Ctr of Delaware, Wilmington

20422

Veterans Administration Med Ctr / Regional AIDS Program, Washington D.C.

23298

Richmond AIDS Consortium, Richmond

30308

AIDS Research Consortium of Atlanta, Atlanta

48201

Comprehensive AIDS Alliance of Detroit, Detroit

48202

Henry Ford Hosp, Detroit

60657

AIDS Research Alliance - Chicago, Chicago

70112

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans

94110

Community Consortium of San Francisco, San Francisco

802044507

Denver CPCRA / Denver Public Hlth, Denver

972109951

Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland

06519

Hill Health Corp, New Haven

071032842

North Jersey Community Research Initiative, Newark

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000969 - A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy | Biotech Hunter | Biotech Hunter